In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Notal Vision Ltd.

www.notalvision.com

Latest From Notal Vision Ltd.

DigiSight Technologies Inc.

DigiSight Technologies Inc.'s cloud-based Paxos platform enables patients with acute ophthalmic conditions to self-administer 10 functional tests, ranging from visual acuity to color discrimination, using an application on a smartphone, tablet or other mobile device.

Medical Device

Visible Progress in Devices for Age-Related Macular Degeneration

A mere seven years ago, before the approval of Visudyne photodynamic therapy, patients losing their vision to age-related macular degeneration (AMD) were told that there was nothing that could be done for them. Today, AMD sufferers may choose from an assortment of drug treatments. Genentech's Lucentis will reach almost $1 billion in sales in its first year on the market, analysts predict, and it doesn't claim to do anything except slow down the progression of the disease. Moreover, the drug does this better than first-generation anti-VEGF drug Macugen. And if those options aren't enough--and they're not--a handful of start-ups developing device-based therapies are making significant progress by applying some highly innovative approaches. ScyFIX, for example, is applying electrical stimulation to halt the effects of AMD and possibly repair the damage done. NeoVista is applying radiation therapy to the back of the eye, an approach that could serve as an alternative to Lucentis and other drugs based on growth factors, which require frequent injections into the eye. Retina Implant has developed an implantable microchip that will stimulate intact nerve cells in the retina to recreate the sense of sight.
Medical Device Combination Products
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • Therapeutic Areas
  • Ophthalmic > Retinopathy > Macular Degeneration
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Notal Vision Ltd.
  • Senior Management
  • Quinton Oswald, CEO
    Jim Long, CFO
    Susan Orr, OD, CMO
  • Contact Info
  • Notal Vision Ltd.
    Phone: (972) 3 6293763
    Clal Bldg. 17th Fl.
    5 Droyanov St.
    Tel Aviv, 63143
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register